BioNTech adds to TCR arsenal with Medigene’s PRAME, platforms

BioNTech is adding to its diverse suite of tumor-targeting TCRs via a deal with Medigene that brings in both a preclinical candidate and broader access to platform technologies, and boosts the profile of one of the oldest players in the TCR space.

The partners announced Monday a collaboration to discover and develop TCR cell therapies based on platform technologies from  Medigene AG (Xetra:MDG1), against solid tumor targets selected by BioNTech SE (NASDAQ:BNTX). BioNTech also acquired Medigene’s preclinical TCR construct against the solid tumor target PRAME, and gained licenses to its costimulatory switch receptor and TCR pairing platforms...